Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Advanced Malignant Solid Tumors 2Thymoma 1Small Cell Lung Carcinoma 1Carcinoma, Non-Small-Cell Lung 1Advanced Cancer 1

Interventions

Sunitinib 3Thymectomy 2Taxes 2Prednisone 2Pemetrexed 2Paclitaxel 2Octreotide 2Imatinib Mesylate 2Erlotinib Hydrochloride 2Cisplatin 2Carboplatin 2vorolanib 1regorafenib 1pembrolizumab 1olaparib 1lenvatinib 1entinostat 1bosutinib 1belinostat 1atezolizumab 1anetumab ravtansine 1amrubicin 1Ramucirumab 1Radiotherapy 1Radiosurgery 1Radiofrequency Ablation 1Psychiatric Rehabilitation 1Prednisolone 1Patient Comfort 1Palliative Care 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Thymoma × vorolanib × Clear all
NCT03583086 2024-10-08

Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors

Vanderbilt-Ingram Cancer Center

Phase 1/2 Completed
88 enrolled 20 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Thymoma, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡